All data are based on the daily closing price as of July 18, 2025
p

PeptiDream

4587.TSE
10.90 USD
-0.26
-2.33%

Overview

Last close
10.90 usd
Market cap
1.41B usd
52 week high
19.95 usd
52 week low
8.26 usd
Target price
23.84 usd

Valuation

P/E
14.307
Forward P/E
39.0625
Price/Sales
4.5338
Price/Book Value
3.8289
Enterprise Value
1.30B usd
EV/Revenue
4.1401
EV/EBITDA
8.2178

Key financials

Revenue TTM
314.14M usd
Gross Profit TTM
232.11M usd
EBITDA TTM
154.86M usd
Earnings per Share
0.77 usd
Dividend
N/A usd
Total assets
541.52M usd
Net debt
-108.03M usd

About

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. It also involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. It has a collaboration with Novartis Pharma AG. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
  • Symbol
    4587.TSE
  • Exchange
    TSE
  • Isin
    JP3836750004
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Dr. Patrick Crawford Reid Ph.D.
  • Headquarter
    Kawasaki
  • Web site
    https://www.peptidream.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top